World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
30094
World Ranking
10538
National Ranking
5422

Marcos de Lima publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marcos de Lima sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 821 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marcos de Lima D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marcos de Lima sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marcos de Lima is affiliated with The Ohio State University in the United States and has contributed extensively to the field of medicine, with a strong focus on hematology and oncology. Their research spans over 383 publications, with significant work in subfields such as hematology, oncology, public health, genetics, and immunology.

The main topics of Marcos de Lima's research include:

  • CAR-T cell therapy research
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Immune Cell Function and Interaction

They have published frequently in several specialized venues, demonstrating ongoing contributions in their areas of expertise. The most frequent publication venues include:

  • Blood
  • Transplantation and Cellular Therapy
  • Bone Marrow Transplantation
  • Biology of Blood and Marrow Transplantation
  • Clinical Lymphoma Myeloma & Leukemia

Marcos de Lima has collaborated with various co-authors over their career. Notable frequent co-authors include:

  • Paolo F. Caimi
  • Leland Metheny
  • Ehsan Malek
  • Wael Saber
  • Folashade Otegbeye

Several recent papers illustrate their research focus, including:

  • NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network
  • A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients, 2020, Blood Advances
  • Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents, 2020, Virology Journal
  • Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma, 2021, Frontiers in Immunology
  • Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network

Best Publications

  • Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

    Vanderson Rocha;Myriam Labopin;Guillermo Sanz;William Arcese

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

    Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva

  • Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

    Margaret R. O'Donnell;Martin S. Tallman;Camille N. Abboud;Jessica K. Altman

  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

    Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell

  • Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

    Marcos De Lima;Athanasios Anagnostopoulos;Mark Munsell;Munir Shahjahan

  • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure

    Michel Duval;John P. Klein;Wensheng He;Jean Yves Cahn

  • Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

    Mohamed L. Sorror;Sergio Giralt;Brenda M. Sandmaier;Brenda M. Sandmaier;Marcos J.G. de Lima

  • Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

    Issa F Khouri;Peter McLaughlin;Rima M Saliba;Chitra Hosing

  • Acute myeloid leukemia, version 3.2019

    Martin S. Tallman;Eunice S. Wang;Jessica K. Altman;Frederick R. Appelbaum

  • Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing

    Krishna V. Komanduri;Lisa S. St. John;Marcos J.G. de Lima;John McMannis

  • Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

    Nelli Bejanyan;Daniel J. Weisdorf;Brent R. Logan;Brent R. Logan;Hai Lin Wang

  • Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

    Christopher G. Kanakry;Paul V. O'Donnell;Terry Furlong;Marcos J. De Lima

  • Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

    Elihu Estey;Marcos de Lima;Raoul Tibes;Sherry Pierce

  • Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.

    M. de Lima;J. McMannis;A. Gee;K. Komanduri

  • Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GVHD

    Daniel R. Couriel;Chitra Hosing;Rima M Saliba;Elizabeth Shpall

  • Tumor necrosis factor-α blockade for the treatment of acute GVHD

    Daniel Couriel;Rima Saliba;Krystal Hicks;Cindy Ippoliti

  • High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

    Stefan O. Ciurea;Marcos J.G. de Lima;Pedro Cano;Martin Korbling

  • Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Celso A. Rodrigues;Guillermo Sanz;Claudio G. Brunstein;Jaime Sanz

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Partow Kebriaei
Partow Kebriaei The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
Mei-Jie Zhang
Mei-Jie Zhang Medical College of Wisconsin
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but looking for alternative or complementary routes, there are several online degrees and career pathways worth exploring. For those interested in nursing, there are nursing programs without TEAS that make entry into this rewarding field more accessible, especially for those who want to avoid standardized test barriers.

If management and leadership roles appeal to you, a healthcare administration degree online accredited can open doors to administrative and executive roles in hospitals, clinics, or public health organizations.

Registered nurses seeking career advancement or expanded clinical responsibilities can consider ADN to NP bridge programs to become nurse practitioners without starting over.

Nutrition and wellness is another vital area in healthcare. If dietary science interests you, check out the best online food science degree programs and explore careers in public health, sports medicine, or wellness coaching. These diverse online options provide flexible ways to enter or grow in the health professions.

Best Scientists Citing Marcos de Lima

Trending Scientists

Recently Published Articles